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Abstract
Background: Multidrug-resistant Pseudomonas aeruginosa is a serious challenge for antimicrobial therapy of nosocomial
infections, as it possesses several mechanisms of antimicrobial resistance. In Central Greece, a sudden increase of infections
caused by carbapenem-resistant P. aeruginosa was observed during 2011, indicating the need for further analysis.
Methods: Five-hundred and sixty-eight P. aeruginosa isolates were collected consecutively during an 8-month period in
2011 from inpatients treated in three hospitals in the Thessaly region (1,000,000 habitants) of Greece. Carbapenem-
resistant P. aeruginosa (n = 284) were characterized by antimicrobial susceptibility testing and β-lactamase content, and
the genetic relatedness of carbapenemase-producing isolates was assessed by BOX-PCR, multilocus sequence typing,
and eBURST analysis. Mapping of the class I integrons of Verona integron-encoded metallo-β-lactamase (VIM)-carrying
isolates was also performed, and clinical data of the VIM producers were reviewed.
Results: Eighty (14.1%) out of the 568 P. aeruginosa isolates recovered from clinical specimens were VIM producers.
Multilocus sequence typing revealed high prevalence of the international clones ST111 and ST235 among blaVIM-2-
and blaVIM-4-positive isolates, respectively. blaVIM-17 was identified in an isolate of a novel sequence type (ST1457).
blaVIM gene cassettes were carried by five distinct class I integrons, including two novel ones.
Conclusions: Since the first report of VIM-producing P. aeruginosa in 2000, this microorganism still remains among the
most prevalent multidrug resistant pathogens in Greece. The spread of VIM-producers belonging to the most common
international clones (ST111 and ST235), the spread of integrons of divergent structures, and the emergence of novel
integrons underscore their ongoing evolution.
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Background
P. aeruginosa is a leading cause of nosocomial infections,
especially in immunocompromised patients. The high
prevalence of multidrug-resistant (MDR) P. aeruginosa
is a serious challenge for antimicrobial therapy. MDR
P. aeruginosa possesses several mechanisms of anti-
microbial resistance; over-expression of the intrinsic
AmpC-type cephalosporinase, which confers resistance
to ceftazidime, inactivation or down-regulation of the
OprD porin, conferring resistance to carbapenems, and
upregulation of the MexAB-OprM or other efflux pumps
of the resistance-nodulation-cell division family, which
can also confer resistance to carbapenems, as well as to
quinolones, and in some cases, to aminoglycosides [1].
Acquired resistance to β-lactams is often reported in
P. aeruginosa as a result of the acquisition of extended
spectrum β-lactamases (ESBLs), such as the PER-1, VEB-1,
TEM, and SHV type ESBLs [2]. Acquired resistance to
carbapenems can also be mediated by the production
of either specific carbapenem-hydrolyzing β-lactamases
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(carbapenemases), such as the metallo-β-lactamases
(MBLs), including the Verona integron-encoded β-
lactamase (VIM) and imipenemase (IMP), or by Klebsiella
pneumoniae carbapenemase (KPC) enzymes and GES/
IBC-like enzymes [3-5]. MBLs hydrolyze almost all
clinically-available β-lactams except monobactams, and
the respective bla genes are often carried on transferable
structures, known as integrons [4]. Nosocomial outbreaks
caused by MBL-producing P. aeruginosa have been re-
ported in several countries worldwide [6-10]. Implementa-
tion of multilocus sequence typing (MLST) has facilitated
the elucidation of the global epidemiology and evolution
of these multidrug-resistant pathogens [11-14].
In the prefecture of Thessaly (Central Greece), the rate
of isolation of carbapenem-resistant P. aeruginosa was
around 33% during the period 2007–2010, but a sudden
increase to 50% was observed in 2011 (E. Petinaki, unpub-
lished data). For this reason, the molecular epidemiology
of carbapenemase-producing P. aeruginosa isolated from
Thessaly was investigated. The genetic context of the
blaVIM genes was also studied.
Methods
Bacterial isolates and antimicrobial susceptibility testing
Five-hundred and sixty-eight P. aeruginosa isolates were
collected from March to October 2011 from the same
number of inpatients treated at three hospitals in Thessaly,
Greece. Three hundred and fifty isolates were recovered
from the University Hospital of Larissa (UHL), a 600-bed
tertiary care hospital, while the remaining isolates were
collected from the general hospitals of Volos and Trikala.
Species identification and antimicrobial susceptibility test-
ing were performed using the Vitek-2 automated system
(BioMerieux Inc., Marcy l′ Etoile, France), according to
the interpretive criteria of the Clinical and Laboratory
Standards Institute [15]. MDR P. aeruginosa are generally
defined as P. aeruginosa resistant to imipenem, ciprofloxa-
cin, and amikacin (minimum inhibitory concentrations
(MICs) of ≥16 mg/L, ≥4 mg/L, and ≥64 mg/L, respect-
ively). ESBL production was tested using the double disk
synergy test. Briefly, disks of ceftazidime, cefotaxime, az-
treonam, and cefepime (30 μg each) were placed at a dis-
tance of 20 mm (center to center) from a disk containing
amoxicillin (AMC, 20 μg) and clavulanic acid (CLA,
10 μg) on Mueller Hinton agar plates [2]. Phenotypic
screening for carbapenemase production was performed
by the modified Hodge-test with a meropenem disk, and
by the imipenem-EDTA double-disk synergy test on
Mueller Hinton agar plates [5].
Detection of β-lactamase genes
DNA was extracted from the carbapenem-resistant
P. aeruginosa using a Quick-gDNA MiniPrep kit (Zymo
Research, Murphy, USA). bla genes were detected by
polymerase chain reaction (PCR), using specific primers
for genes encoding MBLs (blaVIM, blaIMP, blaGIM,
blaNDM, blaSPM, blaSIM), KPC (blaKPC), ESBLs (blaPER,
blaVEB, blaSHV, blaTEM, blaCTX-M, blaGES), and OXA type
β-lactamases (blaOXA-40, blaOXA-48, blaOXA-50), as de-
scribed previously [2,4,16]. The PCR products obtained
from the VIM-positive isolates (n = 80) were sequenced on
both DNA strands using an ABI3730 DNA sequencer
(Applied Biosystems, Warrington, United Kingdom). Nu-
cleotide and deduced protein sequences were identified by
comparing the sequences with the database developed by
Jacoby and Bush (http://www.lahey.org/Studies).
Molecular typing of isolates
Molecular typing was performed by BOX-PCR, as de-
scribed previously [17] for carbapenemase-producing
P. aeruginosa. MLST was performed for 55 representa-
tive of the aforementioned isolates, including all isolates
of the major BOX-patterns and one isolate from each of
the remaining BOX-patterns, as described previously
[14]. Sequences were obtained from both DNA strands,
and allelic profiles were determined and assigned to se-
quence types (STs). Novel alleles and STs were submitted
to the P. aeruginosa MLST website (http://pubmlst.org/
paeruginosa/). Non-overlapping groups of related STs
were identified using eBURST, with the default setting for
the definition of groups (http://eburst.mlst.net) [18].
PCR mapping of class I integrons
Combinations of specific primers for the conserved seg-
ments (5′CS and 3′CS) of class I integrons together with
the blaVIM primers were used for PCR mapping of class
I integrons, as described previously [19]. Both DNA
strands of the PCR products were sequenced using add-
itional primers specific for the blaPSE-1, blaOXA-10, arr-7,
aacA4, aacA7, smr-2, and dfrb genes [19,20], using an
ABI3730 DNA sequencer (Applied Biosystems).
Collection of clinical data
The medical records of patients infected with or colonized
by carbapenemase-producing P. aeruginosa were reviewed
retrospectively. Prior to obtaining the clinical information
for the patients, approval was received from the Ethics
Committee of the UHL, which is represented by the Infec-
tion Control Committee (permission number 1234). The
patients were assumed to have acquired MDR P. aerugi-
nosa prior to hospitalization when the microbe was iso-
lated within 48 h of admission, while colonization with
MDR P. aeruginosa was defined by the absence of relevant
symptoms. Clinical information included age, duration of
hospitalization, previous hospitalization history (history of
transfer from another hospital, hospitalized departments,
and wards), underlying diseases, clinical outcome, medical
care exposures, and antimicrobial therapy.
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Results and discussion
Of the 568 P. aeruginosa isolates, 284 (50%) were identi-
fied as resistant to carbapenems (MICs for imipenem
≥16 mg/L). Of the 284 carbapenem-resistant isolates, 80
(28%) isolates were positive for carbapenemase production
by phenotypic screening and were positive for blaVIM by
PCR. The remaining 204 carbapenem-resistant P. aerugi-
nosa isolates were negative for carbapenemase production
by phenotypic screening and negative for all ESBL and
carbapenemase genes tested. Thus, the carbapenem resist-
ance phenotype of the latter isolates may be attributed to
other resistance mechanisms, such as porin loss, increased
efflux, and AmpC overexpression.
All VIM producers exhibited MDR phenotypes. Apart
from being resistant to imipenem and meropenem
(MICs ≥16 mg/L), all VIM producers showed resistance
to ticarcillin/clavulanate (MICs ≥128 mg/L) and pipera-
cillin/tazobactam (MICs ≥128 mg/L), and intermediate-
resistance or resistance to ceftazidime (MICs of 16 to
≥64 mg/L). In addition to being resistant to β-lactams,
these isolates were also resistant to ciprofloxacin (MICs
≥4 mg/L), and excluding two isolates, to amikacin (MICs
≥64 mg/L), gentamicin (MICs ≥16 mg/L), tobramycin
(MICs ≥16 mg/L), and netilmicin (MICs ≥32 mg/L). All
VIM producers were susceptible to colistin (MICs
≤2 mg/L). The VIM producers showed higher MIC50
values for caftazidime (MICs ≥64 mg/L) and tobramycin
(≥16 mg/L) compared with the non-VIM producing
carbapenem-resistant P. aeruginosa (MICs of 4 mg/L
and 2 mg/L, respectively). No other differences were ob-
served for the MIC range, MIC50, and MIC90 values of
the remaining antimicrobial agents tested.
Of the 80 VIM producers, 48 encoded VIM-2, 31 had
VIM-4, and one isolate contained VIM-17 enzymes. The
monthly distribution of VIM-2 and VIM-4 producers is
shown in Figure 1. An increase in the recovery rates of
VIM-2 producers was observed from March to August
2011, whereas VIM-4 producers were recovered at
higher frequencies in May and September 2011. The
VIM producers were recovered from various wards of
the hospitals, but mainly from the internal medicine
(26%) and intensive care units (ICUs) (13%). Most of the
VIM producers were isolated from urine (20.6%), but
they were also recovered from sputum, blood, bronchial
secretions (13% each), and other clinical specimens.
According to the clinical records, 52 of the 80 VIM-
positive patients were infected, and 28 of 80 were colo-
nized. A retrospective review of the clinical records of the
patients infected with or colonized by VIM-producing P.
aeruginosa was performed. All patients were diagnosed
with an underlying disease at admission (such as solid tu-
mors, diabetes, or cerebrovascular accidents), and 50% had
a high fever. All patients had a previous hospitalization his-
tory (75% had been transferred from another hospital) and
had received therapy with antimicrobial agents of multiple
classes (e.g. penicillin-inhibitor combinations, second and
third-generation cephalosporins, carbapenems, fluoroqui-
nolones, glycopeptides, and cyclic lipopeptides). All but
three cases of patients infected or colonized by VIM-
producing P. aeruginosa were >65 years of age. The major-
ity of infected patients were treated with a combination of
colistin and aminoglycosides.
Two major BOX-PCR patterns were identified: P1
amongst VIM-2 and P2 amongst VIM-4 producers, which
consisted of 21 (26%) and 16 (20%) out of the 80 VIM pro-
ducers, respectively (Table 1). The remaining VIM pro-
ducers were distributed into 18 different BOX-patterns,
each comprised of one to five isolates. Amongst the 55
representative VIM-producers (all isolates of the major
BOX-patterns and one isolate from each of the remaining
BOX-patterns), we identified eight different STs. The
international clones ST111 (clonal complex CC111) and
ST235 (CC235) were the most prevalent, comprising 26
and 21 of the 55 VIM producers genotyped, respectively
(Table 1). Both STs have been reported previously among
VIM producers recovered from the university hospital of
Patras, South Greece [21], and from other European coun-
tries, such as Sweden, Germany, France, Italy, Spain, and
Bulgaria [12,13,21-26].
Five different class I integrons were identified: three
structures coding for VIM-2 (aacA29a|blaVIM-2|aacA29b,
blaVIM-2|aacA7|dfrB, and blaOXA-10|aacA4|blaVIM-2|smr-2),
one for VIM-4 (blaVIM-4|arr-7|aacA4|blaPSE-1), and one for
VIM-17 (aacA29a|blaVIM-17|aacA29b) (Table 1, Figure 2).
Three of the five class I integrons found here have been de-
scribed previously in P. aeruginosa [19,20], whereas in the
remaining two the blaVIM-2 gene was found as part of novel
gene cassette arrays [GenBank: KC527014 and KC527015].
In the current study, the aacA29a|blaVIM-2|aacA29b
gene cassette array (In59-like) has been identified in 45
VIM-2 producers belonging to STs 111, 244, 253, 277,
and 773. The majority of isolates assigned to ST111 were
recovered from ICUs (15 out of 26 ST111 isolates; 58%),
and they were isolated mainly from bronchial secretions
and blood. These results were in concordance with other
studies, where, respiratory care procedures among intu-
bated patients in the ICU have been reported to account
for the spread of MDR P. aeruginosa, and for the high
mortality rates (40–60%) in bacterial nosocomial pneu-
monia and ventilator-associated pneumonia [27]. How-
ever, ST111 isolates were also found in other wards of
our institutions; thus clonal expansion of VIM-2-
producing ST111 isolates was documented. In addition,
STs 244, 253, 277, and 773 carrying the In59-like cas-
sette array were recovered from our internal medicine
units. It is known that VIM-2 producers carrying the
In59-like integron have previously been reported in
Greece [20, GenBank: EU118149]. Single nucleotide
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variants in the 59-base element of aacA29b among VIM-
producers have been described in Sweden, with one isolate
originating from Greece [19, GenBank: AF263519]. The
presence of the In59-like cassette in different strains/gen-
etic backgrounds underscores the recruitment potential
of this integron, and may indicate its association with a
mobile structure.
The blaVIM-4|arr-7|aacA4|blaPSE-1 gene cassette array
has been described in Scandinavia, where it was identi-
fied in two MBL-producers that were imported from
Greece and Cyprus, one of which was also ST235 [20,
GenBank: FN397623]. In the current study, all VIM-4
producers (n = 31) belonged to a single ST (ST235), and
were isolated mainly from urine specimens (15 isolates,
50%) from the internal medicine (12 isolates) and ur-
ology units (ten isolates). However, VIM-4 producers
were also isolated from other wards of the participant
hospitals, suggesting clonal expansion of a single strain.
From March to August 2011, VIM-4 producers of
ST235 were isolated mainly in the internal medicine unit
of UHL, whereas spread of these isolates in the urology
unit was documented in September 2011.
The two novel VIM-2 encoding integrons (blaVIM-2|
aacA7|dfrB and blaOXA-10|aacA4|blaVIM-2|smr-2) were
found in isolates of STs 235 and 395 (Table 1). The bla-
VIM-17 (a variant of blaVIM-2) gene was found in a single
isolate of a novel ST (ST1457), a single locus variant of
ST235. blaVIM-17 was carried by an In59-like structure
that has also been reported in P. aeruginosa from Greece
[20, GenBank: EU118148].
Conclusions
Multidrug-resistant VIM producers comprised 14.1% of
the total P. aeruginosa recovered in Thessaly during
2011. Since the first report of VIM-producing P. aerugi-
nosa in 2000 [28,29], this microorganism remains among
the most prevalent MDR pathogens in Greece. VIM-1,
VIM-2, VIM-4, and VIM-17-producing P. aeruginosa
have been reported previously in Greece [21,28-30]. In
the present study, the association between the genetic
Figure 1 Monthly distribution of a) VIM-2 and b) VIM-4 P. aeruginosa from March to October 2011.
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context and molecular types of VIM-producing P. aeru-
ginosa was assessed. Most (46%) of the VIM producers
belonged to the internationally-distributed clusters of
ST111 and ST235, which carried previously-reported
gene cassettes coding for the VIM-2 and VIM-4 en-
zymes, respectively. Novel VIM-2-carrying integron
structures were identified among sporadic isolates. The
VIM-17 carrying integron was found in an isolate of a
novel ST (ST1457). The findings of this study under-
score the high prevalence of VIM producers among
carbapenem-resistant P. aeruginosa in Thessaly, as well
as their ongoing evolution.
Table 1 Gene cassettes, STs/CCs and BOX-patterns of the VIM-producing P. aeruginosa isolates
Gene cassettesa GenBank; reference No. of isolates ST/CC BOX pattern (no. of isolates)
aacA29a|blaVIM-2 |aacA29b EU118149; [20] 45
111/ CC111 P1 (21)
111/ CC111 P5 (3)
111/ CC111 P9 (4)
111/ CC111 P11 (2)
111/ CC111 P14 (1)
111/ CC111 P16 (5)
244/ CC244 P7 (2)
244/ CC244 P15 (1)
253/ CC253 P4 (1)
277/ CC277 P6 (3)
773 P8 (2)
blaVIM-4|arr-7|aacA4|blaPSE-1 FN397623; [19] 31
235/ CC235 P2 (16)
235/ CC235 P17 (3)
235/ CC235 P18 (3)
235/ CC235 P19 (3)
235/ CC235 P20 (4)
235/ CC235 P10 (2)
aacA29a|blaVIM-17|aacA29b EU118148; [20] 1 1457/ CC235 P3 (1)
blaOXA-10|aacA4|blaVIM-2|smr-2 KC527014; this study 2 395/ CC395 P12 (2)
blaVIM-2| aacA7|dfrB KC527015; this study 1 235/ CC235 P13 (1)
aAminoglycoside (6′) acetyltransferase genes: aacA29a, aacA29b, aacA4, aacA7; β-lactamase genes: blaVIM-2, blaVIM-4, blaVIM-17, blaOXA-10, blaPSE-1; dihydrofolate
reductase type B (trimethoprim resistance) gene: dfrB; ADP-ribosyl transferase (rifampicin resistance) gene: arr-7; small multidrug resistance protein gene: smr-2.
Figure 2 Schematic representation (not to scale) of class I integrons of VIM-carrying P. aeruginosa isolates. The GenBank accession
numbers of the sequences are also indicated.
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